UBS Group
DRMA icon

UBS Group’s Dermata Therapeutics DRMA Stock Holding History

UBS Group’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.7K Sell
16,796
-18,812
-53% -$23.7K ﹤0.01% 8114
2026
Q1 		$43.1K Buy
35,608
+34,371
+2,779% +$57.8K ﹤0.01% 7464
2025
Q4 		$2.87K Sell
1,237
-8,810
-88% -$28.8K ﹤0.01% 9201
2025
Q3 		$50.4K Buy
10,047
+951
+10% +$5.78K ﹤0.01% 7563
2025
Q2 		$53.2K Buy
9,096
+2,067
+29% +$15.9K ﹤0.01% 7716
2025
Q1 		$75.9K Buy
7,029
+5,642
+407% +$69.4K ﹤0.01% 7259
2024
Q4 		$18.7K Buy
1,387
+1,237
+825% +$16K ﹤0.01% 7921
2024
Q3 		$2.46K Sell
150
-21
-12% -$418 ﹤0.01% 8425
2024
Q2 		$4.08K Buy
+171
New +$7.44K ﹤0.01% 8131
2023
Q4 		– Sell
-1
Closed -$139 – 9415
2023
Q3 		$139 Sell
1
-46
-98% -$8.82K ﹤0.01% 8804
2023
Q2 		$11.6K Buy
47
+24
+104% +$6.55K ﹤0.01% 7102
2023
Q1 		$4.44K Buy
23
+7
+44% +$4.08K ﹤0.01% 8189
2022
Q4 		$15.3K Buy
16
+10
+167% +$12.5K ﹤0.01% 7995
2022
Q3 		$8K Buy
6
+1
+20% +$1.56K ﹤0.01% 8699
2022
Q2 		$7K Buy
5
+3
+150% +$6.18K ﹤0.01% 8470
2022
Q1 		$5K Buy
+2
New +$6.83K ﹤0.01% 9108
2021
Q4 		– Hold
0
– -$1K – 10338
2021
Q3 		– Hold
0
– – – 9168

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AA
Advisory Alpha Holland, Michigan $4.08B AUM 20.62% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.8B AUM 19.11% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group's DRMA Position: Q2 2026 in Review

UBS Group reduced its Dermata Therapeutics (DRMA) stake by 53% in Q2 2026, selling an estimated $23.7K and leaving 16,796 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #8114.

UBS Group first reported a position in DRMA in Q1 2022 and has held it in 16 quarters since. The position peaked at $75.9K in Q1 2025. 13 funds tracked by Wall St. Rank hold DRMA as of Q2 2026.

  • UBS Group held 16,796 shares of Dermata Therapeutics worth $21.7K as of Q2 2026.
  • UBS Group sold 18,812 Dermata Therapeutics shares in Q2 2026, an estimated $23.7K.
  • Dermata Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8114 holding.
  • UBS Group first reported a position in Dermata Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • UBS Group's Dermata Therapeutics position peaked at $75.9K in Q1 2025.
  • 13 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.